GILD Gilead Sciences, Inc.

166.53USD-1.45%Mkt Cap: 206.55B USDP/E: —

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, D…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap206.55B USD
Enterprise Value227.79B USD
Revenue (TTM)30.99B USD
Gross Profit23.21B USD
Net Income (TTM)8.51B USD
Revenue/Share24.95 USD
Last Price166.53 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees17.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)16.41
PEG2.27
EV/EBITDA15.54
EV/Revenue7.35
P/S6.67
P/B15.85
EPS (TTM)-3.13 USD
EPS (Forward)10.15 USD
52W Range
116.8883% of range176.58
52W High176.58 USD
52W Low116.88 USD
Profitability
Gross Margin78.83%
Oper. Margin38.23%
EBITDA Margin47.31%
Profit Margin28.90%
ROE37.49%
ROA14.42%
ROIC26.79%
ROCE24.79%
Growth
Revenue Growth6.80%
Earnings Growth-20.20%
Cash Flow & Leverage
Operating CF10.02B USD
CapEx (TTM)563.00M USD
FCF Margin34.45%
FCF Yield5.17%
Net Debt18.28B USD
Net Debt/EBITDA1.25
Net Debt/FCF1.71
Balance Sheet
Debt/Equity1.10
Current Ratio1.38
Quick Ratio1.08
Book Value/Sh10.51 USD
Cash/Share6.41 USD
Dividends
Fwd Div Rate3.28 USD
Trail. Div Rate3.25 USD
Div. Yield1.94%
5Y Avg Yield3.27%
Payout Ratio43.46%
Ex-Div DateDec 15, 2026
Pay DateDec 30, 2026
Splits
Last Split2:1
Split DateJan 28, 2013
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)175.92 USD
Upside (mean)+5.6%
Target Range131.00 USD – 200.00 USD
131.00+5.6% to mean200.00
# Analysts26
Ownership
Shares Out.1.24B
Float1.24B
Insiders0.14%
Institutions91.71%
Short Interest
Short Ratio3.5d
Short % Float1.72%
Short % Out.1.72%
Shares Short21.27M
Short (prev mo.)21.83M
Technical
SMA 50155.43 (+7.1%)
SMA 200141.85 (+17.4%)
Beta0.37
S&P 52W Chg12.08%
Avg Vol (30d)6.21M
Avg Vol (10d)6.01M
Technical Indicators
RSI (14)54.7
MACD3.6415
MACD Signal4.3878
MACD Hist.-0.7463
BB Upper176.39 USD
BB Middle166.77 USD
BB Lower157.15 USD
BB Width11.54%
ATR (14)4.552 USD
Vol Ratio (20d)0.79x

About Gilead Sciences (NASDAQ: GILD)

›

Gilead Sciences (NASDAQ: GILD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 17,000 employees.

The shares were at 166.53 USD on 19 November 2026, up 36.6% over 52 weeks. Its 52-week range is 116.88 USD to 176.58 USD: the price is 5.7% below the high and 42.5% above the low.

Its market capitalisation is 206.55B USD. It pays a dividend yielding 1.94% (it pays out 43% of its earnings), against a median of 2.55% among the dividend payers in that peer group.

Gilead Sciences reports return on equity of 37.5%, an operating margin of 38.2% and revenue up 6.8% year over year.

Its debt exceeds its cash by 18.28B USD, a debt-to-equity ratio of 1.10. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 175.92 USD is 5.6% above the current price. The next earnings report is expected on 9 February 2027.